Vagal mediation of GLP-1's effects on food intake and glycemia

Physiology and Behavior

Volumn 152, Issue , 2015, Pages 372-380

  Krieger, Jean Philippe ^a   Langhans, Wolfgang ^a   Lee, Shin J ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; NEUROPEPTIDE;

BRAIN NERVE CELL; BRAIN STEM; ENERGY BALANCE; FOOD INTAKE; GENETIC MANIPULATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SATIETY; SIGNAL TRANSDUCTION; VAGUS NERVE; VAGUS REFLEX; ANIMAL; EATING; METABOLISM; PHYSIOLOGY;

ANIMALS; EATING; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; HUMANS; VAGUS NERVE;

EID: 84961130037     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2015.06.001     Document Type: Review

References (110)

1. Diakogiannaki E., Gribble F.M., Reimann F. Nutrient detection by incretin hormone secreting cells. Physiol. Behav. 2012, 106:387-393.
2. Bucinskaite V., et al. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol. Motil. 2009, 21:978-e78.
3. Ezcurra M., Reimann F., Gribble F.M., Emery E. Molecular mechanisms of incretin hormone secretion. Curr. Opin. Pharmacol. 2013, 13:922-927.
4. Lim, G. E. & Brubaker, P. L. Glucagon-like peptide 1 secretion by the L-cell - the view from within. Diabetes 55, S70-S77.
5. Kreymann B., Ghatei M.A., Willams G., Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987, 1-5.
6. Drucker D.J., Philippe J., Mojsov S., Chick W.L., Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:3434-3438.
7. Mojsov S., Weir G.C., Habener J.F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 1987, 79:616-619.
8. Punjabi M., Arnold M., Geary N., Langhans W., Pacheco-López G. Peripheral glucagon-like peptide-1 (GLP-1) and satiation. Physiol. Behav. 2011, 1-6. 10.1016/j.physbeh.2011.02.038.
9. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993, 214:829-835.
10. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 1995, 80:952-957.
11. Heymann E., Mentlein R. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett. 1978, 91:360-364.
12. Berthoud H.R., Neuhuber W.L. Functional and chemical anatomy of the afferent vagal system. Autonomic Neuroscience: Basic and Clinical 2000, 85:1-17.
13. Nakagawa A., et al. Receptor Gene Expression of Glucagon-like Peptide-1, But not Glucose-dependent Insulinotropic Polypeptide, in Rat Nodose Ganglion Cells 2004, 1-8. 10.1016/j.autneu.2003.11.001.
14. Nakabayashi H., Nishizawa M., Nakagawa A., Takeda R., Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am. J. Phys. 1996, 271:E808-E813.
15. Kakei M., Yada T., Nakagawa A., Nakabayashi H. Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca. Autonomic Neuroscience: Basic and Clinical 2002, 1-6.
16. Grill H.J., Hayes M.R. Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance. Cell Metab. 2012, 16:296-309.
17. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 1998, 101:515-520.
18. Gutzwiller J.-P., et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999, 44:81-86.
19. Flint A., Raben A., Ersbøll A.K., Holst J.J., Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obes. (Lond) 2001, 25:781-792.
20. Chelikani P.K., Haver A.C., Reidelberger R.D. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. AJP: Regulatory, Integrative and Comparative Physiology 2005, 288:R1695-R1706.
21. Imeryüz N.I., et al. Glucagon-like peptide-1 inhibits gastric emptying via vagalafferent-mediated central mechanisms 1997, 1-9.
22. Larsen P.J., Fledelius C., Knudsen L.B., Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001, 50:2530-2539.
23. Rodriquez de Fonseca F., et al. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metab. Clin. Exp. 2000, 49:709-717.
24. Williams D.L., Baskin D.G., Schwartz M.W. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009, 150:1680-1687.
25. Talsania T., Anini Y., Siu S., Drucker D.J., Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005, 146:3748-3756.
26. Abbott C.R., et al. The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 2005, 1044:127-131.
27. Plamboeck A., et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. AJP: Gastrointestinal and Liver Physiology 2013, 304:G1117-G1127.
28. Kraly F.S., Jerome C., Smith G.P. Specific postoperative syndromes after total and selective vagotomies in the rat. Appetite 1986, 7:1-17.
29. Norgren R., Smith G.P. A method for selective section of vagal afferent or efferent axons in the rat. Am. J. Physiol. 1994, 1136-1141.
30. Walls E.K., et al. Selective vagal rhizotomies: a new dorsal surgical approach used for intestinal deafferentations. Am. J. Phys. 1995, 269:R1279-R1288.
31. Schwartz G.J., Plata-Salamán C.R., Langhans W. Subdiaphragmatic vagal deafferentation fails to block feeding-suppressive effects of LPS and IL-1 beta in rats. Am. J. Phys. 1997, 273:R1193-R1198.
32. Labouesse M.A., et al. Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4. J. Neuroendocrinol. 2012, n/a-n/a. 10.1111/j.1365-2826.2012.02364.x.
33. Hayes M.R., et al. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1. AJP: Regulatory, Integrative and Comparative Physiology 2011, 301:R1479-R1485.
34. Kanoski S.E., Fortin S.M., Arnold M., Grill H.J., Hayes M.R. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011, 152:3103-3112.
35. Ruttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2008, 150:1174-1181.
36. Zhang J., Ritter R.C. Circulating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, nonvagal mechanisms. Am. J. Physiol. 2012.
37. Fujiwara K., et al. Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats. J. Neurochem. 2012, 121:66-76.
38. Secher A., et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J. Clin. Invest. 2014, 10.1172/JCI75276.
39. Sisley S., et al. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J. Clin. Invest. 2014, 10.1172/JCI72434DS1.
40. Dossat A.M., Lilly N., Kay K., Williams D.L. Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J. Neurosci. 2011, 31:14453-14457.
41. Dossat A.M., et al. Nucleus accumbens GLP-1 receptors influence meal size and palatability. AJP: Endocrinology and Metabolism 2013, 304:E1314-E1320.
42. Alhadeff A.L., Rupprecht L.E., Hayes M.R. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012, 153:647-658.
43. Dickson S.L., et al. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J. Neurosci. 2012, 32:4812-4820.
44. Mietlicki-Baase E.G., et al. The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors. AJP: Endocrinology and Metabolism 2013, 305:E1367-E1374.
45. Skibicka K.P., Dickson S.L. Enteroendocrine hormones-central effects on behavior. Curr. Opin. Pharmacol. 2013, 13:977-982.
46. Nishizawa M., Nakabayashi H., Uchida K., Nakagawa A., Niijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J. Auton. Nerv. Syst. 1996, 61:149-154.
47. Ahrén B. Regulatory peptides. Regul. Pept. 2014, 1-3. 10.1016/j.regpep.2014.09.003.
48. Donath M.Y., Burcelin R. GLP-1 effects on islets: hormonal, neuronal, or paracrine?. Diabetes Care 2013, 36(Suppl. 2):S145-S148.
49. Hayes M.R., Mietlicki-Baase E.G., Kanoski S.E., De Jonghe B.C. Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose. Annu. Rev. Nutr. 2014, 34:237-260.
50. Plamboeck A., et al. Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. Eur. J. Endocrinol. 2013, 169:187-201.
51. Nishizawa M., et al. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. AJP: Endocrinology and Metabolism 2013, 305:E376-E387.
52. Burcelin R., Da Costa A., Drucker D., Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001, 50:1720-1728.
53. Vahl T.P., et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007, 148:4965-4973.
54. Balkan B., Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. AJP: Regulatory, Integrative and Comparative Physiology 2000, 279:R1449-R1454.
55. Ahrén B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286:R269-R272.
56. Ahlkvist L., Ahrén B. Inhibiting the cholinergic effector system of the vagus nerve reduces the insulinotropic effects of both GLP-1 and GIP. Diabetologia 2014, 57:1-564.
57. Lamont B.J., et al. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J. Clin. Invest. 2012, 122:388-402.
58. Ionut V., Hucking K., Liberty I.F., Bergman R.N. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 2005, 48:967-975.
59. Dardevet D., et al. Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G806-G814.
60. Seghieri M., et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 2013, 56:156-161.
61. Ohlsson L., et al. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. Diabetes Obes. Metab. 2013, 15:531-537.
62. Behme M.T., Dupré J., McDonald T.J. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr. Disord. 2003, 3(3).
63. Dupré, J. et al. Glucagon-like Peptide I Reduces Postprandial Glycemic Excursions in IDDM.
64. Creutzfeldt W.O., et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996.
65. Kielgast U., Krarup T., Holst J.J., Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011, 34:1463-1468.
66. Ghazi T., Rink L., Sherr J.L., Herold K.C. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care 2014, 37:210-216.
67. Farngren J., Persson M., Schweizer A., Foley J.E., Ahrén B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. The Journal of Clinical Endocrinology & Metabolism 2012, 97:3799-3806.
68. Jun L.S., et al. Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production. Diabetes 2015, 64:819-827.
69. Omar B.A., et al. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 2014, 63:101-110.
70. Nishizawa M., et al. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E1027-E1036.
71. Schwartz M.W., et al. Cooperation between brain and islet in glucose homeostasis and diabetes. Nature 2014, 503:59-66.
72. Jarrad M., Scarlett M.W.S. Gut-brain mechanisms controlling glucose homeostasis. F1000 Prime Reports 2015, 7.
73. Ahrén B. Hepato-incretin function of GLP-1: novel concept and target in type 1 diabetes. Diabetes 2015, 64:715-717.
74. de Lartigue G. Putative role of neuropeptides in vagal afferent signaling. Physiol. Behav. 2014, 1-15. 10.1016/j.physbeh.2014.03.011.
75. Baraboi E.-D., St-Pierre D.H., Shooner J., Timofeeva E., Richard D. Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. AJP: Regulatory, Integrative and Comparative Physiology 2011, 301:R1011-R1024.
76. Yamamoto H., et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J. Neurosci. 2003, 23:2939-2946.
77. Sumal K.K., Blessing W.W., Joh T.H., Reis D.J., Pickel V.M. Synaptic interaction of vagal afferents and catecholaminergic neurons in the rat nucleus tractus solitarius. Brain Res. 1983, 277:31-40.
78. Appleyard S.M., et al. Visceral afferents directly activate catecholamine neurons in the solitary tract nucleus. J. Neurosci. 2007, 27:13292-13302.
79. Guevara-Aguilar R., Jimenez-Montufar L.L., Garcia-Diaz D.E., Wayner M.J., Armstrong D.L. Olfactory and visceral projections to the paraventricular nucleus. Brain Res. Bull. 1988, 20:799-801.
80. Rinaman L. Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure. Brain Res. 2010, 1350:18-34.
81. Rinaman L. Visceral sensory inputs to the endocrine hypothalamus. Front. Neuroendocrinol. 2007, 28:50-60.
82. Cowley M.A., et al. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 1999, 24:155-163.
83. McKinley M.J. The physiological regulation of thirst and fluid intake. News Physiol. Sci. 2004, 19:1-6.
84. Gold R.M. Hypothalamic obesity: the myth of the ventromedial nucleus. Science 1973, 182:488-490.
85. Sims J.S., Lorden J.F. Effect of paraventricular nucleus lesions on body weight, food intake and insulin levels. Behav. Brain Res. 1986, 22:265-281.
86. Michaud J.L., et al. Sim1 haploinsufficiency causes hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus. Hum. Mol. Genet. 2001, 10:1465-1473.
87. Holder, J. L., Butte, N. F. & Zinn, A. R. Profound Obesity Associated With a Balanced Translocation That Disrupts the SIM1 Gene. http://oxfordjournals.org/.
88. Hayes M.R., Skibicka K.P., Grill H.J. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 2008, 149:4059-4068.
89. Rinaman L., Card J.P., Schwaber J.S., Miselis R.R. Ultrastructural demonstration of a gastric monosynaptic vagal circuit in the nucleus of the solitary tract in rat. J. Neurosci. 1989, 9:1985-1996.
90. Tang-Christensen M., et al. Central Administration of GLP-1-(7-36)Amide Inhibits Food and Water Intake in Rats 2002, 1-9.
91. Nadkarni P., Chepurny O.G., Holz G.G. Regulation of glucose homeostasis by GLP-1. Prog. Mol. Biol. Transl. Sci. 2014, 121.
92. Paton J.F., Li Y.W., Deuchars J., Kasparov S. Properties of solitary tract neurons receiving inputs from the sub-diaphragmatic vagus nerve. NSC 2000, 95:141-153.
93. de Lartigue G., Dimaline R., Varro A., Dockray G.J. Cocaine- and amphetamine-regulated transcript: stimulation of expression in rat vagal afferent neurons by cholecystokinin and suppression by ghrelin. J. Neurosci. 2007, 27:2876-2882.
94. Broberger C., Holmberg K., Kuhar M.J., Hökfelt T. Cocaine- and amphetamine-regulated transcript in the rat vagus nerve: a putative mediator of cholecystokinin-induced satiety. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13506-13511.
95. Zheng H., Patterson L.M., Berthoud H.-R. CART in the dorsal vagal complex: sources of immunoreactivity and effects on Fos expression and food intake. Brain Res. 2002, 957:298-310.
96. Skofitsch G., Jacobowitz D.M., Zamir N. Immunohistochemical localization of a melanin concentrating hormone-like peptide in the rat brain. Brain Res. Bull. 1985, 15:635-649.
97. Zamir N., Skofitsch G., Jacobowitz D.M. Distribution of immunoreactive melanin-concentrating hormone in the central nervous system of the rat. Brain Res. 1986, 373:240-245.
98. Zamir, N., Skofitsch, G., Bannon, M. J. & Jacobowitz, D. M. Melanin-concentrating Hormone: Unique Peptide Neuronal System in the Rat Brain and Pituitary Gland.
99. de Lartigue G., et al. EGR1 is a target for cooperative interactions between cholecystokinin and leptin, and inhibition by ghrelin, in vagal afferent neurons. Endocrinology 2010, 151:3589-3599.
100. Ronveaux C.C., de Lartigue G., Raybould H.E. Ability of GLP-1 to decrease food intake is dependent on nutritional status. Physiol. Behav. 2014, 135:222-229.
101. Duca F.A., Sakar Y., Covasa M. Combination of obesity and high-fat feeding diminishes sensitivity to GLP-1R agonist, exendin-4. Diabetes 2013, 10.2337/db12-1204.
102. Duca F.A., Swartz T.D., Sakar Y., Covasa M. Decreased intestinal nutrient response in diet-induced obese rats: role of gut peptides and nutrient receptors. Int. J. Obes. (Lond) 2012, 10.1038/ijo.2012.45.
103. Punjabi M., et al. Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance. Endocrinology 2014, 155:1690-1699.
104. Liu C., et al. PPARg in vagal neurons regulates high-fat diet induced thermogenesis. Cell Metab. 2014, 19:722-730.
105. de Lartigue G., Ronveaux C.C., Raybould H.E. Deletion of leptin signaling in vagal afferent neurons results in hyperphagia and obesity. Mol Metab 2014, 3:595-607.
106. Scott M.M., Williams K.W., Rossi J., Lee C.E., Elmquist J.K. Leptin receptor expression in hindbrain Glp-1 neurons regulates food intake and energy balance in mice. J. Clin. Invest. 2011, 121:2413-2421.
107. Stirling L.C., et al. Nociceptor-specific gene deletion using heterozygous NaV1.8-Cre recombinase mice. Pain 2005, 113:27-36.
108. Calik M.W., Radulovacki M., Carley D.W. A method of nodose ganglia injection in Sprague-Dawley rat. J. Vis. Exp. 2014, 10.3791/52233.
109. McClelland J., Bozhilova N., Campbell I., Schmidt U. A systematic review of the effects of neuromodulation on eating and body weight: evidence from human and animal studies. Eur. Eat. Disord. Rev. 2013, 21:436-455.
110. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2012, 8:728-742.